このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

NHL/CLL患者におけるhuCART19-IL18

2026年11月11日 更新者:University of Pennsylvania

再発または難治性CD19 +非ホジキンリンパ腫(NHL)および慢性リンパ性白血病(CLL)の患者におけるhuCART19-IL18細胞の第I相試験

The purpose of this study is to evaluate the safety and feasibility of huCART19-IL18 cells in patients with relapsed or refractory CD19+ cancers.

調査の概要

詳細な説明

This is a Phase I study to assess the safety, tolerability, manufacturing feasibility, pharmacokinetics, and preliminary efficacy of huCART19-IL18 cells in patients with CD19+ cancers. The study will take place in two parts: an initial Dose-Finding Phase and an Expansion Phase. In the dose-finding phase, the maximum tolerated dose will be determined using a Bayesian Optimal Interval (BOIN) design within each of the following disease-specific cohorts:

  • Cohort A: Non-Hodgkin Lymphoma (Active, Not Recruiting)
  • Cohort B: Chronic Lymphocytic Leukemia (Active, Not Recruiting)
  • Cohort C: Acute Lymphoblastic Leukemia (Active, Not Recruiting)
  • Cohort D (Expansion Phase): Non Hodgkin Lymphoma and Acute Lymphoblastic Leukemia (Active, Not Recruiting) will evaluate changes to cell activation method in the huCART19-IL18 manufacturing process using the recommended dose for expansion (RDE) arising out of the dose-finding phase.

研究の種類

介入

入学 (推定)

72

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Pennsylvania
      • Philadelphia、Pennsylvania、アメリカ、19104
        • University of Pennsylvania

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Signed informed consent form

  2. Documentation of CD19 expression on malignant cells by flow cytometry/IHC from a CLIA certified laboratory

    NHL Patients: Within 6 months of physician-investigator confirmation of eligibility as long as there has been no intervening CD19 directed therapy since expression confirmed. Results outside of this window may be used, if there is no accessible tumor site and the subject did not receive intervening CD19 directed therapy since CD19 expression was confirmed.

    CLL and ALL Patients: At time of most recent relapse. If the subject has subsequently received CD19-directed therapy since this result was obtained, repeating testing must be performed to determine eligibility.

  3. Patients with relapsed disease after prior allogeneic SCT must meet the following criteria:

    a. Have no active GVHD and require no immunosuppression b. Are more than 6 months from transplant at the time of physician-investigator confirmation of eligibility

  4. Adequate organ function defined as:

    a. Creatinine ≤ 1.6 mg/dl b. ALT/AST ≤ 3x upper limit of normal range c. Direct bilirubin ≤ 2.0 mg/dl, unless the subject has Gilbert's syndrome (≤3.0 mg/dl) d. Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygen > 92% on room air e. Left Ventricle Ejection Fraction (LVEF) ≥ 40% confirmed by ECHO/MUGA

  5. Evidence of active disease within 12 weeks of physician-investigator confirmation of eligibility. .

  6. Male or female age ≥ 18 years.

  7. ECOG Performance Status that is either 0 or 1.

  8. Subjects of reproductive potential must agree to use acceptable birth control methods.

  9. Disease-specific criteria:

NHL Patients (Cohorts A and D):

i. Patients with any of the following diagnoses: Diffuse Large B-cell Lymphoma not otherwise specified (DLBCL NOS), germinal center or activated B-cell types;Primary Cutaneous DLBCL; Primary Mediastinal (thymic) Large B-cell Lymphoma; ALK+ Anaplastic Large B-cell Lymphoma; High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 rearrangements (i.e., "Double or Triple Hit"); High-grade B-cell Lymphoma, NOS; T-cell Rich B-cell Lymphoma; Transformed Follicular Lymphoma; or any aggressive B-cell lymphoma arising from indolent lymphoma.

1. Patients must have either relapsed after, or be ineligible for, prior CAR T cell therapy, and meet one of the following criteria:

  1. Relapsed/refractory disease after at least 2 prior lines of appropriate therapy; OR

  2. Relapsed/refractory disease after autologous SCT; OR

  3. Relapsed/refractory disease after allogeneic SCT. ii. Follicular lymphoma

    1. Patients must have either relapsed after, or be ineligible for, prior commercial CAR T cell therapy; AND
    2. Received at least 2 prior lines of appropriate therapy (not including single agent monoclonal antibody therapy) and progressed within 2 years after second or higher line of therapy.

iii. Mantle cell lymphoma

  1. Patients must have either failed standard of care CAR T cell therapy (e.g., Tecartus™, etc) or other investigational CAR T cell product, OR be ineligible for standard of care Tecartus™; and

  2. Patients must also meet one of the following criteria:

    1. Relapsed/refractory disease after at least 2 prior lines of appropriate therapy, including a BTK inhibitor. Single-agent monoclonal antibody therapy does not count towards prior lines of therapy; OR
    2. Relapsed/refractory disease after prior autologous SCT; OR
    3. Relapsed/refractory disease after prior allogeneic SCT.

CLL Patients (Cohort B):

i. Chronic Lymphocytic Leukemia

  1. Patients with relapsed/refractory disease after at least 2 prior lines of appropriate therapy; AND
  2. Patients must have previously received or be intolerant to an approved BTK inhibitor and venetoclax, unless a BTK inhibitor or venetoclax is contraindicated.

ii. Large cell transformation of CLL (Richter's Transformation)

1. Patients must be primary refractory or received at least 1 prior line of treatment for Richter's Transformation.

c. ALL Patients (Cohorts C and D): i. Patients with b-cell acute lymphoblastic leukemia. Note: Chronic myeloid leukemia (CML) lymphoid blast crisis is considered a sub-type of relapsed B-ALL, thus will be encompassed in our definition of B-ALL throughout; AND ii. Patients with 2nd or greater relapse or refractory disease as defined by one of the following criteria:

  1. Recurrent disease in the blood or bone marrow identified morphologically, by IHC or flow; OR

  2. Isolated CNS disease. Note: Patients with prior/current history of CNS3 disease will only be eligible for treatment if the CNS disease is responsive to therapy; OR

  3. Recurrent extramedullary disease at other (non-CNS) sites if disease response can be assessed radiographically. Note: Patients with recurrent extramedullary disease do not need to have detectable blood or bone marrow involvement; OR

  4. Any relapse after allogeneic SCT; OR

  5. Patients with refractory disease as defined by one of the following:

    1. Failure to achieve remission (<5% bone marrow blasts or ongoing extramedullary or CNS disease) after 2 cycles of induction chemotherapy; OR
    2. Patients that achieve remission but remain MRD+ after ≥2 cycles of induction chemotherapy.

Exclusion Criteria:

  1. Active hepatitis B, active hepatitis C, or other active, uncontrolled infection.

  2. Class III/IV cardiovascular disability according to the New York Heart Association Classification.

  3. Clinically apparent arrhythmia or arrhythmias that are not stable on medical management within two weeks of physician-investigator confirmation of eligibility.

  4. Active acute or chronic GVHD requiring systemic therapy.

  5. Dependence on systemic steroids or immunosuppressant medications. For additional details regarding use of steroid and immunosuppressant medications.

  6. RETIRED WITH PROTOCOL AMENDMENT V7

  7. Receipt of prior huCART19 therapy.

  8. CNS disease as defined by disease-cohort as follows:

    1. NHL/CLL Patients: Active CNS disease. Note: Patients with a history of CNS involvement that was successfully treated are eligible. A CNS evaluation is only required for eligibility if a subject is experiencing signs/symptoms of CNS involvement.
    2. ALL Patients: CNS3 disease that is progressive on therapy, or with CNS parenchymal lesions that might increase the risk of CNS toxicity.
  9. Pregnant or nursing (lactating) women.

  10. Patients with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system, and unrelated to their cancer or previous cancer treatment.

  11. Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to ≥ 10mg of prednisone. Patients with autoimmune neurologic diseases (such as MS) will be excluded.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Cohort A: NHL Dose Level 1a (DL1a)

3x10^6 huCART19-IL18 cells administered as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

実験的:Cohort A: NHL Dose Level -1 (DL-1)

7x10^5 huCART19-IL18 cells administered as a single intravenous (IV) infusion or slow IV push; This dose level will only be explored if at least one DLT is observed at Dose Level 1a.

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

実験的:Cohort A: NHL Dose Level 1b (DL1b)

3x10^6 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

実験的:Cohort A: NHL Dose Level 2 (DL2)

7x10^6 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

実験的:Cohort A: NHL Dose Level 3 (DL3)

3x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

実験的:Cohort A: NHL Dose Level 4 (DL4)

7x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

実験的:Cohort A: NHL Dose Level 5 (DL5)

3x10^8 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

実験的:Cohort B: CLL Dose Level 1b (DL1b)

3x10^6 huCART19-IL18 cells administered as a single intravenous (IV) infusion or slow IV push; This dose level will only be explored if at least one DLT is observed at Dose Level 2.

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

実験的:Cohort B: CLL Dose Level 2 (DL2)

7x10^6 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

実験的:Cohort B: CLL Dose Level 3 (DL3)

3x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

実験的:Cohort B: CLL Dose Level 4 (DL4)

7x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

実験的:Cohort B: CLL Dose Level 5 (DL5)

3x10^8 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

実験的:Cohort C: ALL Dose Level 1b (DL1b)

3x10^6 huCART19-IL18 cells administered as a single intravenous (IV) infusion or slow IV push; This dose level will only be explored if at least one DLT is observed at Dose Level 2.

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

実験的:Cohort C: ALL Dose Level 2 (DL2)

7x10^6 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

実験的:Cohort C: ALL Dose Level 3 (DL3)

3x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

実験的:Cohort C: ALL Dose Level 4 (DL4)

7x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

実験的:Cohort C: ALL Dose Level 5 (DL5)

3x10^8 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

実験的:Cohort D: NHL

7x10^6 huCART19-IL18 as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

実験的:Cohort D: ALL

7x10^6 huCART19-IL18 as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0
時間枠:Up to 15 years post-huCART19-IL18 infusion

Cohorts A-C: Type, frequency and severity of adverse events as assessed by CTCAE V5.0. Each disease-specific cohort will be analyzed separately.

Up to 15 years post-huCART19-IL18 infusion
Occurrence of dose-limiting toxicities (DLTs)
時間枠:28 days post-huCART19-IL18 infusion

Cohorts A-C: Unacceptable toxicity as defined by the protocol. DLTs will be evaluated separately by each disease-specific cohort.

28 days post-huCART19-IL18 infusion
Determination of Maximum Tolerated Dose (MTD)
時間枠:28 days post-huCART19-IL18 infusion

Cohorts A-C: Selected based on an isotonic regression model. The MTD will be established separately by disease-specific cohort.

28 days post-huCART19-IL18 infusion
Determination of a recommended dose for expansion (RDE)
時間枠:3 months post-huCART19-IL18 infusion

Cohorts A-C: Evaluated by Cohort/dose level using a multi-criteria decision analysis.

3 months post-huCART19-IL18 infusion
Proportion of manufactured products that meet the product release criteria
時間枠:3 months

Cohort D: Calculated based on the proportion of subjects with huCART19-IL18 products that fail to meet the product release criteria, out of the number of subjects in whom manufacturing was attempted.

3 months
Proportion of manufactured products that meet the assigned dose
時間枠:3 months

Cohort D: Calculated based on the proportion of subjects with huCART19-IL18 products that fail to meet the assigned dose, out of the number of subjects in whom manufacturing was attempted.

3 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Proportion of manufacturing products that meet the product release criteria
時間枠:3 months

Cohorts A-C: Calculated based on the proportion of subjects with huCART19-IL18 products that fail to meet the product release criteria, out of the number of subjects in whom manufacturing was attempted. Will be evaluated separately by each disease-specific cohort.

3 months
Proportion of manufactured products that meet the assigned dose
時間枠:3 months

Cohorts A-C: Calculated based on the proportion of subjects with huCART19-IL18 products that fail to meet the assigned dose, out of the number of subjects in whom manufacturing was attempted. Will be evaluated separately by each disease-specific cohort.

3 months
Incidence of Treatment-Emergent Adverse Events
時間枠:3 months

Cohort D: Type, frequency and severity of adverse events as assessed by CTCAE V5.0.

3 months
Overall Response Rate (ORR)
時間枠:3 months post-huCART19-IL18 infusion

NHL and CLL Patients: The proportion of subjects with CR or PR at Month 3 as compared to baseline.

3 months post-huCART19-IL18 infusion
Overall Response Rate (ORR)
時間枠:1 month post-huCART19-IL18 infusion

ALL Patients: The proportion of subjects with CR/CRi/CR(MRD-) at Day 28 as compared to baseline

1 month post-huCART19-IL18 infusion
Best Overall Response (BOR)
時間枠:12 months post-huCART19-IL18 infusion

NHL and CLL Patients: The proportion of subjects with a best overall disease response of CR or PR between Month 3 and Month 12, and prior to the start of new anticancer therapy.

12 months post-huCART19-IL18 infusion
Best Overall Response (BOR)
時間枠:6 months post-huCART19-IL18 infusion

ALL Patients: The proportion of subjects with CR/CRi/CR(MRD-) by Month 6, and prior to the start of new anticancer therapy.

6 months post-huCART19-IL18 infusion
Duration of Response (DOR)
時間枠:Up to 15 years post-huCART19-IL18 infusion

NHL and CLL Patients: Duration from the date when CR/PR is first met at/after Month 3, to the date of relapse, death, or receipt of new anticancer therapy.

Up to 15 years post-huCART19-IL18 infusion
Duration of Remission (DOR)
時間枠:Up to 15 years post-huCART19-IL18 infusion

ALL Patients: Duration from the date when CR/CRi/CR(MRD-) is first met to the date of relapse, death or receipt of new anticancer therapy

Up to 15 years post-huCART19-IL18 infusion
Progression-Free Survival (PFS)
時間枠:12 monthsUp to 15 years post-huCART19-IL18 infusion

NHL and CLL Patients: Duration of time from the huCART19-IL18 infusion to the date of the disease progression/relapse, death or receipt of new anticancer therapy

12 monthsUp to 15 years post-huCART19-IL18 infusion
Event-Free Survival (EFS)
時間枠:Up to 15 years post-huCART19-IL18 infusion

ALL Patients: Duration of time from the huCART19-IL18 infusion to the date of relapse/treatment failure, death or receipt of new anticancer therapy.

Up to 15 years post-huCART19-IL18 infusion
Overall Survival (OS)
時間枠:Up to 15 years post-huCART19-IL18 infusion

Duration of time from the huCART19-IL18 infusion to the date of death, for any reason

Up to 15 years post-huCART19-IL18 infusion
Characterize low level disease and B cell assessment in response to huCART19-IL18 cells by Flow Cytometry
時間枠:12 months

Polychromatic flow cytometry-based assessment of leukemia and B cells, extent and duration of leukemic response

12 months
Characterize low level disease and B cell assessment in response to huCART19-IL18 cells by Next Gen Sequencing
時間枠:12 months

Presence or absence of malignant B cells by Next-Generation Immunoglobulin heavy chain Sequencing (NGIS)

12 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Jakub Svoboda, MD、University of Pennsylvania

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年5月6日

一次修了 (推定)

2036年5月1日

研究の完了 (推定)

2036年5月1日

試験登録日

最初に提出

2020年12月11日

QC基準を満たした最初の提出物

2020年12月21日

最初の投稿 (実際)

2020年12月24日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月11日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する